 Andrea Bonetto
Concepts (283)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cachexia | 31 | 2023 | 52 | 11.370 |
Why?
| | Muscular Atrophy | 17 | 2023 | 74 | 3.390 |
Why?
| | Muscle, Skeletal | 29 | 2023 | 1447 | 3.150 |
Why?
| | Colorectal Neoplasms | 6 | 2022 | 617 | 2.280 |
Why?
| | Neoplasms | 13 | 2023 | 2118 | 2.260 |
Why?
| | Ovarian Neoplasms | 5 | 2023 | 407 | 1.820 |
Why?
| | Liver Neoplasms | 5 | 2021 | 521 | 1.760 |
Why?
| | STAT3 Transcription Factor | 5 | 2021 | 174 | 1.500 |
Why?
| | Activin Receptors, Type II | 3 | 2021 | 8 | 1.500 |
Why?
| | Myostatin | 6 | 2016 | 17 | 1.400 |
Why?
| | Wasting Syndrome | 2 | 2020 | 11 | 1.110 |
Why?
| | Osteocytes | 4 | 2022 | 22 | 1.080 |
Why?
| | Bone and Bones | 5 | 2021 | 283 | 1.080 |
Why?
| | Mice | 29 | 2023 | 15052 | 1.020 |
Why?
| | Colonic Neoplasms | 4 | 2021 | 222 | 0.920 |
Why?
| | Interleukin-6 | 6 | 2023 | 677 | 0.900 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 1361 | 0.860 |
Why?
| | Bone Neoplasms | 2 | 2021 | 194 | 0.840 |
Why?
| | Animals | 36 | 2023 | 32102 | 0.830 |
Why?
| | Camptothecin | 3 | 2019 | 97 | 0.820 |
Why?
| | Disease Models, Animal | 11 | 2022 | 3580 | 0.810 |
Why?
| | Bone Diseases, Metabolic | 1 | 2021 | 53 | 0.760 |
Why?
| | Osteosarcoma | 1 | 2021 | 66 | 0.750 |
Why?
| | Neuropeptides | 1 | 2021 | 65 | 0.740 |
Why?
| | Body Composition | 3 | 2018 | 580 | 0.720 |
Why?
| | Muscles | 2 | 2013 | 326 | 0.710 |
Why?
| | Antineoplastic Agents | 4 | 2022 | 1893 | 0.630 |
Why?
| | Muscle Fibers, Skeletal | 4 | 2021 | 169 | 0.610 |
Why?
| | Muscle Proteins | 5 | 2013 | 209 | 0.600 |
Why?
| | Muscular Dystrophies | 1 | 2017 | 36 | 0.590 |
Why?
| | Bone Density | 2 | 2018 | 432 | 0.580 |
Why?
| | Cell Line, Tumor | 8 | 2021 | 2751 | 0.550 |
Why?
| | Stomach Neoplasms | 2 | 2013 | 66 | 0.520 |
Why?
| | Insulin-Like Growth Factor I | 3 | 2013 | 281 | 0.510 |
Why?
| | Adenocarcinoma | 2 | 2021 | 799 | 0.500 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 275 | 0.480 |
Why?
| | Head and Neck Neoplasms | 3 | 2022 | 425 | 0.410 |
Why?
| | Janus Kinases | 1 | 2012 | 13 | 0.410 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2021 | 1147 | 0.400 |
Why?
| | X-Ray Microtomography | 3 | 2022 | 79 | 0.390 |
Why?
| | Acute-Phase Reaction | 1 | 2011 | 39 | 0.390 |
Why?
| | Inflammation | 2 | 2023 | 2499 | 0.360 |
Why?
| | Down-Regulation | 4 | 2010 | 601 | 0.350 |
Why?
| | Energy Metabolism | 3 | 2020 | 715 | 0.350 |
Why?
| | Glutamine | 1 | 2010 | 91 | 0.350 |
Why?
| | Musculoskeletal Diseases | 2 | 2022 | 55 | 0.350 |
Why?
| | Follistatin | 1 | 2009 | 12 | 0.340 |
Why?
| | Muscular Disorders, Atrophic | 1 | 2009 | 3 | 0.340 |
Why?
| | Valproic Acid | 1 | 2009 | 43 | 0.330 |
Why?
| | Hydroxamic Acids | 1 | 2009 | 80 | 0.330 |
Why?
| | Male | 23 | 2022 | 55949 | 0.330 |
Why?
| | Leucovorin | 3 | 2019 | 42 | 0.330 |
Why?
| | Humans | 28 | 2023 | 115589 | 0.320 |
Why?
| | Mitochondria, Muscle | 2 | 2020 | 92 | 0.310 |
Why?
| | Cell Line | 5 | 2021 | 2651 | 0.310 |
Why?
| | Fluorouracil | 3 | 2019 | 151 | 0.310 |
Why?
| | Femur | 2 | 2021 | 194 | 0.310 |
Why?
| | Signal Transduction | 9 | 2021 | 4541 | 0.300 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2009 | 199 | 0.300 |
Why?
| | Ubiquitin-Protein Ligases | 4 | 2013 | 139 | 0.290 |
Why?
| | Glycogen Synthase Kinase 3 | 3 | 2013 | 77 | 0.280 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2010 | 1137 | 0.280 |
Why?
| | Female | 18 | 2023 | 59913 | 0.270 |
Why?
| | Antioxidants | 1 | 2009 | 533 | 0.260 |
Why?
| | DNA, Ribosomal | 2 | 2022 | 80 | 0.240 |
Why?
| | Mitochondria | 3 | 2022 | 750 | 0.230 |
Why?
| | Osteoclasts | 2 | 2021 | 34 | 0.230 |
Why?
| | Mice, Inbred C57BL | 6 | 2021 | 4773 | 0.230 |
Why?
| | Mice, Transgenic | 2 | 2022 | 1970 | 0.210 |
Why?
| | Cytokines | 4 | 2022 | 1853 | 0.210 |
Why?
| | Cytochromes | 1 | 2022 | 9 | 0.210 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2022 | 15 | 0.210 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2022 | 42 | 0.210 |
Why?
| | Heterografts | 2 | 2022 | 119 | 0.200 |
Why?
| | Up-Regulation | 3 | 2016 | 820 | 0.200 |
Why?
| | Free Tissue Flaps | 1 | 2022 | 32 | 0.190 |
Why?
| | Postoperative Complications | 3 | 2022 | 2161 | 0.190 |
Why?
| | Osteolysis | 1 | 2021 | 12 | 0.190 |
Why?
| | Subcutaneous Tissue | 1 | 2021 | 17 | 0.190 |
Why?
| | Receptors, Immunologic | 1 | 2022 | 203 | 0.190 |
Why?
| | Cisplatin | 1 | 2022 | 263 | 0.190 |
Why?
| | Mitochondrial Proteins | 1 | 2022 | 219 | 0.180 |
Why?
| | Muscle Weakness | 1 | 2021 | 80 | 0.180 |
Why?
| | RNA, Ribosomal | 1 | 2021 | 157 | 0.180 |
Why?
| | HCT116 Cells | 1 | 2020 | 69 | 0.170 |
Why?
| | Membrane Glycoproteins | 1 | 2022 | 431 | 0.170 |
Why?
| | Ribosomes | 1 | 2021 | 148 | 0.170 |
Why?
| | Ligands | 1 | 2021 | 569 | 0.170 |
Why?
| | Epoprostenol | 1 | 2020 | 133 | 0.170 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2019 | 32 | 0.160 |
Why?
| | Receptors, Ghrelin | 1 | 2018 | 7 | 0.160 |
Why?
| | Muscle Strength | 2 | 2019 | 275 | 0.160 |
Why?
| | Ghrelin | 1 | 2018 | 33 | 0.160 |
Why?
| | Protein Kinase Inhibitors | 2 | 2016 | 790 | 0.160 |
Why?
| | Sarcopenia | 1 | 2020 | 64 | 0.160 |
Why?
| | Nutrition Assessment | 1 | 2018 | 75 | 0.160 |
Why?
| | Tripartite Motif Proteins | 3 | 2013 | 29 | 0.150 |
Why?
| | Frailty | 1 | 2020 | 116 | 0.150 |
Why?
| | Muscle Contraction | 1 | 2021 | 397 | 0.150 |
Why?
| | Survival Analysis | 1 | 2021 | 1219 | 0.150 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 56 | 0.150 |
Why?
| | Organ Size | 1 | 2018 | 434 | 0.150 |
Why?
| | Stroke Volume | 1 | 2020 | 509 | 0.140 |
Why?
| | Drug Therapy | 1 | 2017 | 78 | 0.140 |
Why?
| | Mice, Inbred Strains | 1 | 2017 | 399 | 0.140 |
Why?
| | Hyperglycemia | 1 | 2020 | 294 | 0.140 |
Why?
| | Education, Medical | 1 | 1999 | 225 | 0.140 |
Why?
| | Metformin | 1 | 2020 | 278 | 0.140 |
Why?
| | Organoplatinum Compounds | 1 | 2016 | 40 | 0.140 |
Why?
| | MicroRNAs | 1 | 2022 | 607 | 0.130 |
Why?
| | Glycogen Synthase Kinase 3 beta | 3 | 2013 | 60 | 0.130 |
Why?
| | Flavonoids | 1 | 2016 | 68 | 0.130 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2016 | 66 | 0.130 |
Why?
| | Myoblasts | 1 | 2016 | 74 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 147 | 0.130 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 924 | 0.130 |
Why?
| | SKP Cullin F-Box Protein Ligases | 2 | 2013 | 8 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 165 | 0.130 |
Why?
| | RNA, Messenger | 3 | 2022 | 2574 | 0.130 |
Why?
| | Muscle Fatigue | 1 | 2016 | 86 | 0.130 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 263 | 0.130 |
Why?
| | Organ Specificity | 1 | 2016 | 273 | 0.130 |
Why?
| | Gene Expression | 1 | 2020 | 1436 | 0.120 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 242 | 0.120 |
Why?
| | Patient Discharge | 1 | 2020 | 770 | 0.120 |
Why?
| | Educational Measurement | 2 | 1993 | 262 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 1870 | 0.120 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 722 | 0.120 |
Why?
| | Disease Progression | 1 | 2021 | 2418 | 0.110 |
Why?
| | School Admission Criteria | 1 | 1993 | 20 | 0.110 |
Why?
| | Reactive Oxygen Species | 2 | 2019 | 549 | 0.100 |
Why?
| | Statistics, Nonparametric | 1 | 2013 | 390 | 0.100 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2010 | 166 | 0.100 |
Why?
| | Cricetulus | 1 | 2012 | 99 | 0.100 |
Why?
| | CHO Cells | 1 | 2012 | 140 | 0.100 |
Why?
| | Mutant Proteins | 1 | 2012 | 96 | 0.100 |
Why?
| | Cricetinae | 1 | 2012 | 260 | 0.100 |
Why?
| | Reproducibility of Results | 2 | 2016 | 2800 | 0.100 |
Why?
| | End Stage Liver Disease | 1 | 2013 | 74 | 0.100 |
Why?
| | Weight Loss | 3 | 2011 | 633 | 0.100 |
Why?
| | Nitriles | 1 | 2012 | 152 | 0.100 |
Why?
| | General Surgery | 1 | 1993 | 129 | 0.090 |
Why?
| | Caveolin 3 | 1 | 2011 | 3 | 0.090 |
Why?
| | Valerates | 1 | 2010 | 3 | 0.090 |
Why?
| | Education, Medical, Undergraduate | 1 | 1993 | 174 | 0.090 |
Why?
| | Liver Cirrhosis | 1 | 2013 | 238 | 0.090 |
Why?
| | Mice, Nude | 1 | 2012 | 639 | 0.090 |
Why?
| | Oxidative Stress | 2 | 2022 | 1093 | 0.090 |
Why?
| | Muscular Diseases | 1 | 2011 | 104 | 0.090 |
Why?
| | Proteasome Inhibitors | 1 | 2010 | 40 | 0.090 |
Why?
| | Biomarkers | 2 | 2018 | 3467 | 0.090 |
Why?
| | Mice, Inbred BALB C | 2 | 2010 | 1168 | 0.090 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 544 | 0.090 |
Why?
| | Nutritional Status | 2 | 2013 | 289 | 0.090 |
Why?
| | Neoplasms, Experimental | 2 | 2010 | 153 | 0.080 |
Why?
| | Italy | 3 | 2005 | 92 | 0.080 |
Why?
| | Neuraminidase | 1 | 2009 | 22 | 0.080 |
Why?
| | Pyrimidines | 1 | 2012 | 376 | 0.080 |
Why?
| | Aging | 1 | 2019 | 1631 | 0.080 |
Why?
| | Pyrazoles | 1 | 2012 | 362 | 0.080 |
Why?
| | Rats | 6 | 2020 | 5034 | 0.080 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2010 | 81 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2020 | 1749 | 0.080 |
Why?
| | Neoplasm Transplantation | 1 | 2009 | 235 | 0.080 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2010 | 224 | 0.080 |
Why?
| | Enzyme Inhibitors | 2 | 2009 | 757 | 0.080 |
Why?
| | Cytosol | 1 | 2009 | 209 | 0.080 |
Why?
| | Liver | 2 | 2019 | 1690 | 0.080 |
Why?
| | Rats, Wistar | 4 | 2010 | 368 | 0.080 |
Why?
| | Nutritional Support | 1 | 2008 | 27 | 0.080 |
Why?
| | Quality of Life | 1 | 2018 | 2385 | 0.080 |
Why?
| | Teaching | 3 | 2005 | 224 | 0.070 |
Why?
| | Heart Failure | 1 | 2020 | 1963 | 0.070 |
Why?
| | Autophagy | 1 | 2009 | 236 | 0.070 |
Why?
| | Protein Processing, Post-Translational | 1 | 2009 | 401 | 0.070 |
Why?
| | Gene Expression Regulation | 3 | 2010 | 2353 | 0.070 |
Why?
| | Transcriptome | 1 | 2011 | 736 | 0.070 |
Why?
| | Transforming Growth Factor beta | 1 | 2008 | 446 | 0.060 |
Why?
| | Aged | 4 | 2021 | 19250 | 0.060 |
Why?
| | Role Playing | 1 | 2005 | 4 | 0.060 |
Why?
| | Myocardium | 1 | 2011 | 926 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2012 | 3914 | 0.060 |
Why?
| | Education, Medical, Continuing | 1 | 2005 | 119 | 0.060 |
Why?
| | Middle Aged | 4 | 2020 | 26998 | 0.060 |
Why?
| | Cytochrome P-450 CYP1A2 | 1 | 2023 | 2 | 0.060 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2023 | 8 | 0.060 |
Why?
| | Child | 1 | 2022 | 18489 | 0.050 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2023 | 39 | 0.050 |
Why?
| | Culture Media, Conditioned | 1 | 2022 | 105 | 0.050 |
Why?
| | Mice, SCID | 1 | 2022 | 321 | 0.050 |
Why?
| | Cathepsin K | 1 | 2021 | 1 | 0.050 |
Why?
| | Tartrate-Resistant Acid Phosphatase | 1 | 2021 | 3 | 0.050 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2021 | 24 | 0.050 |
Why?
| | Vacuolar Proton-Translocating ATPases | 1 | 2021 | 13 | 0.050 |
Why?
| | Carcinoma, Lewis Lung | 1 | 2021 | 13 | 0.050 |
Why?
| | Lipolysis | 1 | 2021 | 39 | 0.050 |
Why?
| | 3T3 Cells | 1 | 2021 | 137 | 0.050 |
Why?
| | Apoptosis | 2 | 2021 | 2377 | 0.050 |
Why?
| | Myeloid Cells | 1 | 2022 | 127 | 0.050 |
Why?
| | Physician-Patient Relations | 1 | 2005 | 465 | 0.050 |
Why?
| | Microglia | 1 | 2022 | 203 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2022 | 400 | 0.040 |
Why?
| | Receptors, Leptin | 1 | 2020 | 24 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2022 | 12608 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 362 | 0.040 |
Why?
| | Adipocytes | 1 | 2021 | 188 | 0.040 |
Why?
| | Estrogens | 1 | 2022 | 315 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2021 | 526 | 0.040 |
Why?
| | Receptors, LDL | 1 | 2019 | 39 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 390 | 0.040 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2020 | 175 | 0.040 |
Why?
| | Europe | 1 | 1999 | 336 | 0.040 |
Why?
| | Surgical Flaps | 1 | 2020 | 121 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2020 | 225 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 930 | 0.040 |
Why?
| | Biopsy | 2 | 2013 | 1056 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 2011 | 2207 | 0.040 |
Why?
| | Ubiquitin | 2 | 2010 | 64 | 0.040 |
Why?
| | Imidazoles | 1 | 2019 | 217 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2021 | 555 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2020 | 1178 | 0.040 |
Why?
| | Risk Factors | 2 | 2020 | 8697 | 0.040 |
Why?
| | Sex Factors | 1 | 2022 | 1736 | 0.040 |
Why?
| | Metabolic Syndrome | 1 | 2020 | 324 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2020 | 432 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2019 | 677 | 0.030 |
Why?
| | Heart | 1 | 2020 | 608 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2019 | 479 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 1856 | 0.030 |
Why?
| | Health Status | 1 | 2020 | 728 | 0.030 |
Why?
| | Homeostasis | 1 | 2019 | 577 | 0.030 |
Why?
| | Age Factors | 1 | 2022 | 2907 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 2604 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1310 | 0.030 |
Why?
| | Metabolomics | 1 | 2019 | 538 | 0.030 |
Why?
| | Glucose | 1 | 2019 | 904 | 0.030 |
Why?
| | Curriculum | 1 | 1999 | 852 | 0.030 |
Why?
| | Body Mass Index | 1 | 2020 | 1971 | 0.030 |
Why?
| | Rectus Abdominis | 1 | 2013 | 9 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2020 | 3022 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2020 | 1008 | 0.030 |
Why?
| | Prognosis | 1 | 2020 | 3339 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2019 | 1700 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2020 | 1078 | 0.020 |
Why?
| | DNA Primers | 1 | 2013 | 514 | 0.020 |
Why?
| | Electroporation | 1 | 2010 | 32 | 0.020 |
Why?
| | Sarcoglycans | 1 | 2010 | 4 | 0.020 |
Why?
| | Dystroglycans | 1 | 2010 | 7 | 0.020 |
Why?
| | Evans Blue | 1 | 2010 | 6 | 0.020 |
Why?
| | Bortezomib | 1 | 2010 | 41 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 6417 | 0.020 |
Why?
| | Adult | 2 | 2022 | 30719 | 0.020 |
Why?
| | Boronic Acids | 1 | 2010 | 33 | 0.020 |
Why?
| | Random Allocation | 1 | 2010 | 337 | 0.020 |
Why?
| | Mutation | 2 | 2011 | 3364 | 0.020 |
Why?
| | Forkhead Transcription Factors | 1 | 2010 | 171 | 0.020 |
Why?
| | Pyrazines | 1 | 2010 | 70 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 345 | 0.020 |
Why?
| | Alkalies | 1 | 2009 | 7 | 0.020 |
Why?
| | Cathepsin B | 1 | 2009 | 14 | 0.020 |
Why?
| | Cathepsin L | 1 | 2009 | 9 | 0.020 |
Why?
| | Students, Medical | 1 | 1993 | 277 | 0.020 |
Why?
| | Cathepsins | 1 | 2009 | 22 | 0.020 |
Why?
| | Cysteine Endopeptidases | 1 | 2009 | 61 | 0.020 |
Why?
| | Atrophy | 1 | 2009 | 152 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 6165 | 0.020 |
Why?
| | Lysosomes | 1 | 2009 | 125 | 0.020 |
Why?
| | Glycoproteins | 1 | 2010 | 309 | 0.020 |
Why?
| | Obesity | 1 | 2020 | 2517 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1000 | 0.020 |
Why?
| | Dexamethasone | 1 | 2009 | 316 | 0.020 |
Why?
| | Body Weight | 1 | 2010 | 867 | 0.020 |
Why?
| | Formoterol Fumarate | 1 | 2006 | 8 | 0.020 |
Why?
| | Pentoxifylline | 1 | 2006 | 21 | 0.020 |
Why?
| | Ethanolamines | 1 | 2006 | 20 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2006 | 58 | 0.020 |
Why?
| | Blotting, Western | 1 | 2008 | 1153 | 0.020 |
Why?
| | Adrenergic beta-Agonists | 1 | 2006 | 129 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2008 | 1227 | 0.020 |
Why?
| | Energy Intake | 1 | 2008 | 414 | 0.020 |
Why?
| | Learning | 1 | 2005 | 358 | 0.010 |
Why?
| | Emotions | 1 | 2005 | 477 | 0.010 |
Why?
| | Insulin | 1 | 2009 | 2082 | 0.010 |
Why?
|
|
Bonetto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|